Insmed Incorporated announced that Chief Financial Officer (CFO) Sara Bonstein will be stepping down from her role. In the same announcement, the company reaffirmed its full-year 2026 financial guidance for its key products.
Key Details
- Executive Transition: CFO Sara Bonstein will depart from the company effective October 30, 2026. A search for a successor is underway.
- Reason for Departure: The separation is not related to any disagreement on the company’s accounting practices, financial statements, or operations.
- Reaffirmed 2026 Guidance: The company reaffirmed revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI® and $450 million to $470 million for ARIKAYCE®.